The fate of 168 New Jersey suits against the makers of hormone replacement drugs has been thrown into doubt with the summary dismissal of the first two of the cases slated for trial.
Superior Court Judge Jamie Happas, the designated judge for all N.J. cases alleging hormone replacement therapy (HRT) drugs caused breast cancer, ruled on July 11 that the state Products Liability Act’s rebuttable presumption of adequate labeling applied and that the plaintiffs failed to surmount it.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]